Aequus Pharmaceuticals (TSE:AQS) has released an update.
Aequus Pharmaceuticals Inc. has seen a positive second quarter in 2024 with a notable increase in revenue and a reduction in net losses compared to the previous year. The company reported a 12% rise in revenue and a decrease in net losses by 2.55% for the quarter, attributing this improvement to greater sales of ZIMED® PF and effective cost-cutting measures.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.
